Published 30 day notice

50162

Federal Register / Vol. 88, No. 146 / Tuesday, August 1, 2023 / Notices

each county that is included in the
proposed expansion, and those
members live near enough to their
Tribe’s seat of government to maintain
close social and economic ties with
their Tribe. According to the leadership
for each of the Tribes, those members
live close enough to regularly
participate in-person in Tribal affairs,
events, activities, or other functions
held by or carried out by the Tribe
within its current PRCDA. Furthermore,
the proposed counties and independent
cities form a contiguous area with the
existing PRCDAs. Considering the
Tribes collectively, the IHS has
determined the additional counties and
independent cities proposed for
inclusion herein to be geographically
proximate, meaning ‘‘on or near,’’ to the
area analogous to reservations for the
seven Mid-Atlantic Tribes.
4. PRC programs operated by/for the
seven Mid-Atlantic Tribes will use their
existing Federal allocation for PRC
funds to provide services to the
expanded population. No additional
financial resources will be allocated by
the IHS to these programs to provide
services to members residing in the
expanded counties and independent
cities in the Commonwealth of Virginia,
State of Maryland, or State of North
Carolina.
This Notice does not contain
reporting or recordkeeping requirements
subject to prior approval by the Office
of Management and Budget under the
Paperwork Reduction Act of 1995.
Roselyn Tso,
Director, Indian Health Service.
[FR Doc. 2023–16275 Filed 7–31–23; 8:45 am]
BILLING CODE 4165–16–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for the Collection of Customer
Participation and Performance
Management With NIH Programs,
Processes, Products, and Services
(National Institutes of Health)
AGENCY:

National Institutes of Health,

HHS.
lotter on DSK11XQN23PROD with NOTICES1

ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has

SUMMARY:

VerDate Sep<11>2014

18:34 Jul 31, 2023

Jkt 259001

submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or using the
search function.
FOR FURTHER INFORMATION CONTACT:
Diane Kreinbrink, Program Manager,
Office of Management Policy and
Compliance, National Cancer Institute,
9609 Medical Center Drive, Room
2W446, Bethesda, Maryland, 20892 or
call non-toll-free number (240) 276–
7283 or email your request, including
your address to: diane.kreinbrink@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on May 8, 2023, page 29681
(Vol. 88, No. 88 FR 29681) and allowed
60 days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection Title: Generic
Clearance for the Collection of Customer
Participation and Performance
Management with NIH Programs,
Processes, Products, and Services (NIH),
0925–XXXX: Expiration Date XX/XX/
XXXX, NEW, National Institutes of
Health (NIH).

PO 00000

Frm 00064

Fmt 4703

Sfmt 4703

Need and Use of Information
Collection: Evaluating the effectiveness
of leadership, programs, and services is
essential for the vitality of any
institution. Leadership review at NIH
focuses on the productivity of the IC,
management of resources and budget
allocations, training activities, and
influence on dimensions of diversity,
accessibility, inclusion, promotion of
investigators and staff (including NIH
Equity Committee (NEC) reports), and
positive workforce culture.
Program and service reviews may
focus on operational performance;
outputs, outcomes, and impacts; policy
compliance, stewardship, diversity,
equity, accessibility, and inclusion.
Reviews and evaluations may solicit
input from IC staff and leadership (IC
Director, Deputy Director, E.O.) and
relevant program participants and
stakeholders about the program’s
effectiveness, leader, or process. They
may include comparisons with other ICs
or programs, external benchmarks, and
outcome metrics where appropriate and
applicable. This input should provide
meaningful information that can be used
to identify strengths and areas that need
improvement. Reports developed from
the review or evaluation may be
presented and shared as needed by the
program when necessary. Such reports
may include recommendations and
proposed actions to address areas for
improvement. In public or broadly
shared reports, any sensitive
information in the reviews or
evaluations will be summarized and
presented in aggregate.
This clearance will allow direct
assessment and measurement of the
customer/respondent base for
participation in and satisfaction with
NIH programs, processes, products, and
services. The clearance will also enable
offices to assess participants’ experience
and accomplishments during or since
participation and their preferences for
existing and future programming,
products, and services. The information
collected using these tools informs and
supports budgeting, program
management and design, program
planning, results reporting, information
dissemination, process improvement,
and outreach initiatives.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,833.

E:\FR\FM\01AUN1.SGM

01AUN1

50163

Federal Register / Vol. 88, No. 146 / Tuesday, August 1, 2023 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondent
Individuals, Households, Private Sector, State
Government, Local Government, Tribal Government,
or Federal Government.

Totals .......................................................................

Dated: July 27, 2023.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2023–16315 Filed 7–31–23; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health

lotter on DSK11XQN23PROD with NOTICES1

National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.

VerDate Sep<11>2014

18:34 Jul 31, 2023

Jkt 259001

Number of
respondents

Form name

Average
burden per
response
(in hours)

Total burden
hour

Performance
Measurement.

500

1

30/60

250

Program Monitoring.
Program Evaluations.
Grantee Effectiveness.
Resource Management.
Feedback ............
Forms ..................

500

1

15/60

125

500

1

45/60

375

1,000

1

15/60

250

500

1

10/60

83

5,000
3,000

1
1

15/60
30/60

1,250
1,500

........................

11,000

........................

3,833

.............................

Name of Committee: National Cancer
Institute Special Emphasis Panel; June 2023
Cycle 44 NExT SEP Committee Meeting.
Date: August 17, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20852 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, Maryland
20817, 301–496–4291, mroczkoskib@
mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, Maryland 20850, 240–276–5683,
toby.hecht2@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 27, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–16277 Filed 7–31–23; 8:45 am]
BILLING CODE 4140–01–P

PO 00000

Number of
responses per
respondent

Frm 00065

Fmt 4703

Sfmt 4703

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the President’s Cancer Panel.
The meeting will be held as a virtual
meeting and open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting can be
accessed by clicking on the following
link: https://nci.rev.vbrick.com/#/
webcasts/presidentscancerpanel.
Name of Committee: President’s Cancer
Panel.
Date: September 7, 2023.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: President’s Cancer Panel National
Cancer Plan Stakeholder Meeting.
Place: National Institutes of Health, 31
Center Drive, Building 31, Room 11A48,
Rockville, MD 20850 (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH 31,
Center Drive, Room 11A48, MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.

E:\FR\FM\01AUN1.SGM

01AUN1